Age-related macular degeneration (AMD) is a leading cause of vision loss among the elderly, characterized by the degeneration of the macula, the central part of the retina responsible for sharp vision. The complexity of AMD necessitates the development of effective preclinical models to study its pathophysiology and evaluate potential therapeutic interventions. At Ace Therapeutics, we specialize in providing comprehensive solutions for the development of rodent models that recapitulate the complex pathology of AMD.
AMD can be classified into two principal forms: dry (non-exudative) AMD and wet (exudative) AMD.
The multifactorial nature of AMD involves various risk factors, including genetic predisposition, oxidative stress, inflammation, and environmental influences such as diet and light exposure. Rodent models are invaluable in this disease as they allow researchers to manipulate specific genetic and environmental factors, thereby mimicking the pathophysiological features of AMD observed in humans. These models provide a platform for studying disease mechanisms, testing potential therapies, and understanding the complex interactions between different biological pathways involved in AMD.
Fig. 1. A schematic diagram featuring the stages of age-related macular degeneration (AMD) with its associated risk factors. (Soundara Pandi SP, et al., 2021)
At Ace Therapeutics, the commitment to advancing AMD research is reflected in the development of customized rodent models tailored to the specific needs of researchers. Our Experts utilize cutting-edge techniques, including CRISPR gene editing, transgenic modifications, and drug induction methods, to recapitulate the various aspects of AMD. By providing these specialized models, Ace Therapeutics empowers researchers to explore the nuances of AMD pathology and evaluate therapeutic interventions effectively.
We provide a comprehensive suite of services for the development and validation of AMD rodent models. Our expertise lies in developing models that closely mimic human AMD, supporting the discovery and evaluation of novel therapeutics.
Gene-Editing Services for AMD Research
We utilize gene-editing technologies, including CRISPR/Cas9, to create knockout (KO), knockin (KI), and transgenic (TG) mouse models. These models are designed to target specific genes implicated in AMD, such as VEGFA, which plays a critical role in neovascularization. By modifying these genes, we can investigate the molecular pathways involved in AMD development and progression.
Ace Therapeutics is dedicated to providing customized models that enable comprehensive research into the mechanisms of AMD and the exploration of potential therapeutic strategies. For more information about our customized rodent models and how we can assist you in your AMD research, please do not hesitate to contact us.
Reference